Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (341-350 of 347) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 347 results.
Cancer Communications (London, England)|April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
Nature Medicine|January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.
Journal of Hematology & Oncology|March 17, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Bo Jia, Wei Xu, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studiesSheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Cancer Communications (London, England)|June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trialYuankai Shi, Kaijian Lei, Yuming Jia, et al.
Pageof 35

Showing results (341-350 of 347) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 347 results.
Cancer Communications (London, England)|April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
Nature Medicine|January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.
Journal of Hematology & Oncology|March 17, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Bo Jia, Wei Xu, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studiesSheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Cancer Communications (London, England)|June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trialYuankai Shi, Kaijian Lei, Yuming Jia, et al.
Pageof 35